pharmaphorum7mon
Novartis gets FDA OK for first in its trio of IgAN therapies
Novartis has claimed accelerated approval from the FDA for a second indication for Fabhalta – IgA nephropathy (IgAN) – as it charts a course to blockbuster sales for the drug. The US regulator ...
pharmaphorum6d
Biogen shows its IgAN hand with felzartamab data
Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...
Nature3mon
The Oxford classification—predicting progression of IgAN
The IgAN group needs to be congratulated for coordinating a worldwide effort to develop a universally accepted IgAN classification system. By developing agreed definitions for each pathological ...
Nature3y
Breaking new ground with a late-phase rare-disease pipeline
Having been the first company to deliver positive phase 3 data in the rare disease immunoglobulin A nephropathy (IgAN), Calliditas is awaiting regulatory approval decisions in the US and European ...